While chronic dosing might be a nice feature for a new chemical entity whose manufacturer is looking for long-term sales potential, less frequent administration would be preferred by patients and might expand the market opportunity. Less frequent dosing also may decrease side effects and increase efficacy of certain biologics by maintaining more consistent levels of drug in the patient's system.

InfiMed Therapeutics Inc. intends to provide manufacturers of protein and peptide drugs with the less frequent dosing option. Its technologies for sustained release drug delivery use polyethylene glycol (PEG)-based hydrogels that can be administered as intramuscular or subcutaneous depot injections. Release of drug is controlled by degradation of the hydrogel in the body - the timing of which can be controlled by altering the characteristics of the hydrogel.